Advertisement

DNA Topoisomerase II Poisons and the Cell Cycle

  • P. J. Smith
Part of the Developments in Oncology book series (DION, volume 77)

Abstract

Nuclear DNA, a target for many anticancer drugs, does not exist inside a human cell as an extended, relaxed and unrestrained molecule. Rather, in its protein-associated form of chromatin it is highly organized with order being imposed by specific DNA-protein interactions. The imposition of such restraints on the free movement of DNA molecules within the nucleus means that any topological problems must be actively resolved by the topoisomerase enzymes (1). The major type II enzyme, DNA topoisomerase II, is strategically located at the base of chromatin loop domains to carry out its housekeeping functions and operates by forming temporary gates in double stranded DNA (Fig. 1) through which an intact helix can pass. Several classes of antitumor drugs are now recognized as topoisomerase poisons because of their ability to trap the enzyme gates on DNA in the form of stabilized cleavable complexes (Fig. 1).

Keywords

Small Cell Lung Cancer Cell Intercalate Agent Cleavable Complex Cell Cycle Delay Cell Cycle Perturbation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wang IC: DNA topoisomerases. Annu. Rev. Biochem. 54:665–697, 1985.PubMedCrossRefGoogle Scholar
  2. 2.
    Liu LF: DNA topoisomerase poisons as antitumour drugs. Annu. Rev. Biochem. 58:351–375, 1989.PubMedCrossRefGoogle Scholar
  3. 3.
    Smith PJ: DNA topoisomerase dysfunction: A new goal for antitumor chemotherapy. BioEssays 12: 167–172, 1990.PubMedCrossRefGoogle Scholar
  4. 4.
    Kapusinski J, Darzynkiewicz Z, Traganos F, Melamed MR: Interaction of a new antitumour agent, 1-4-dihydroxy-5, 8-bis [[[2- [2-hydroxyethyl] amino] ethyl] amino]-9, 10-anthracenedione, with nucleic acids. Biochem. Pharmac. 30:231–240, 1981.CrossRefGoogle Scholar
  5. 5.
    Long BH, Musial ST, Brattain MG: Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16–213 and VM26: A quantitative structure-activity relationship. Biochem. 23:1183–1188, 1984.CrossRefGoogle Scholar
  6. 6.
    Wozniak AJ, Ross WE: DNA damage as a basis for 4′-demethylepipodo-phyllotoxin-9- (4, 6–0-ethylidene-2-d-glucopyranoside) (etoposide) cytotoxicity. Cancer Res. 43:120–124, 1983.PubMedGoogle Scholar
  7. 7.
    Lonn U, Lonn S, Nylen U, Winblad G: Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (Etoposide and Teniposide). Cancer Res. 49:6202–6207, 1989.PubMedGoogle Scholar
  8. 8.
    Glisson B, Gupta R, Hodges P, Ross W: Cross resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: Evidence for a common intracellular target. Cancer Res. 46:1939–1942, 1986.PubMedGoogle Scholar
  9. 9.
    Minford J, Pommier Y, Filipski J, et al: Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry 25:9–16, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith PJ, Makinson TA: Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res 49:1118–1124, 1989.PubMedGoogle Scholar
  11. 11.
    Epstein RJ, Watson JV, Smith PJ: Subpopulation analysis of drug-induced cell-cycle delay in human tumour cells using 90° light scatter. Cytometry 9: 349–358, 1988.PubMedCrossRefGoogle Scholar
  12. 12.
    Smith PJ, Anderson CO, Watson JV: Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts. Cancer Res. 46:5641–5645, 1986.PubMedGoogle Scholar
  13. 13.
    Fox ME, Smith PJ: Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumour DNA intercalators mAMSA and mitoxantrone. Cancer Res. 50:5813–5818, 1990PubMedGoogle Scholar
  14. 14.
    Heck MM, Hittelman WN, Earnshaw WC: Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. USA 85:1086–1090, 1988.PubMedCrossRefGoogle Scholar
  15. 15.
    Slevin ML, Clark PI, Joel SP, et al: A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J. Clin. Oncol. 7:1333–1340, 1989.PubMedGoogle Scholar
  16. 16.
    Epstein RJ, Smith PJ: Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II interactive antitumour drugs. Cancer Res. 48:297–303, 1988.PubMedGoogle Scholar
  17. 17.
    Epstein RJ, Smith PJ: Mitogen-induced topoisomerase II synthesis precedes DNA synthesis in human breast cancer cells. Biochem. Biophys. Res. Commun. 160:12–17, 1989.Google Scholar
  18. 18.
    Epstein RJ, Smith PJ, Watson JV, et al: Oestrogen potentiates topoisomerase-II-mediated cytotoxicity in an activated subpopulation of human breast cancer cells: Implications for cytotoxic drug resistant in solid tumours. Int. J. Cancer 44:501–505, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • P. J. Smith

There are no affiliations available

Personalised recommendations